Need for More Comprehensive Evaluation of Immune-Related Adverse Events in Immunotherapy for Biliary Tract Cancer
- PMID: 33090192
- DOI: 10.1001/jamaoncol.2020.4815
Need for More Comprehensive Evaluation of Immune-Related Adverse Events in Immunotherapy for Biliary Tract Cancer
Comment in
-
Need for More Comprehensive Evaluation of Immune-Related Adverse Events in Immunotherapy for Biliary Tract Cancer-Reply.JAMA Oncol. 2020 Dec 1;6(12):1981-1982. doi: 10.1001/jamaoncol.2020.4821. JAMA Oncol. 2020. PMID: 33090188 No abstract available.
Comment on
-
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.JAMA Oncol. 2020 Jun 1;6(6):888-894. doi: 10.1001/jamaoncol.2020.0930. JAMA Oncol. 2020. PMID: 32352498 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
